Prescribing medicines in pregnancy database
Search the prescribing medicines in pregnancy database.
Our database for prescribing medicines in pregnancy is here to help doctors prescribe medicines to pregnant women. It is not for public use or a substitute for a health professional's medical advice. Doctors using this database should not consider it their sole or main resource.
We do not give advice on using medicines in pregnancy for specific cases.
-
PageUnderstand the Australian categorisation system for prescribing medicines in pregnancy.
It is important to understand this categorisation system before using the database.
The database also contains safety information about the medicine. Health professionals should consider this essential information when prescribing medicines to pregnant women. This information may differ from the published Product Information (PI) that comes with the medicine. This is because of ongoing updates to the database.
More information about medicines in pregnancy
If you would like to understand more about medicines in pregnancy, before using the database, you can see:
-
PageUnderstand classes of medicines that are exempted from pregnancy classification and database inclusion.
-
PageFind obstetric drug information services available to health professionals and consumers.
-
You can use eBusiness Services to search product and consumer medicine information documents:
-
Search Consumer medicine information (CMI) or Product information (PI) by medicine, trade name or active ingredient
Updates to the database
We update the database when new information about a medicine used in pregnancy becomes available. You can find updates to the database by:
- using the database search for a specific medicine (see 'Search the database' on this page)
- visiting our news page.
If you get no results when searching
If no results come from your search this may mean:
- The medicine has no pregnancy classification. This means the therapeutic good is exempt from pregnancy categorisation.
- No one has registered the medicine in Australia.
- You may have misspelled the medicine's name.
- You may have used the trade name instead of the name of the active ingredient. You can find the name of the active ingredient by looking up the trade name in the Australian Register of Therapeutic Goods (ARTG).
Search the database
By accessing the database, you acknowledge that you have read, understood, and accept the introductory information provided on the Australian categorisation system for prescribing medicines in pregnancy (see Australian categorisation system for prescribing medicines).
The current (full) database is searchable in the table below by medicine name only. You can also access the database, and use the search function, via TROVE - external site which includes the ability to search by drug class.
Note: the TROVE search is limited to information only available up to 16 August 2022. The searchable database may be updated later to search all medicines currently in the database].
Name | Category | Safety statement | Classification 1 | Classification 2 | Classification 3 |
---|---|---|---|---|---|
abacavir | B3 | Antimicrobials | Antiviral agents | ||
abacavir / dolutegravir / lamivudine | B3 | Antimicrobials | Antiviral agents | ||
abacavir / lamivudine / zidovudine | B3 | Antimicrobials | Antiviral agents | ||
abacavir/ lamivudine | B3 | Antimicrobials | Antiviral agents | ||
abatacept | C | Allergy and Immune System | Immunomodifiers | ||
abciximab | C | All anticoagulants and thrombolytic agents can produce placental haemorrhage and subsequent prematurity and fetal loss. | Cardiovascular System | Anticoagulants and thrombolytic agents | |
abemaciclib | D | Based on results from animal studies and its mechanism of action, abemaciclib may harm the foetus. | Antineoplastic Agents | ||
abiraterone | D | Antiandrogens carry the potential for feminisation of the male fetus at or after 8 weeks post conception and exposure should be avoided during pregnancy. | Endocrine System | Antiandrogens | |
acalabrutinib | C | Based on findings in animals, acalabrutinib may cause fetal harm. | Antineoplastic Agents | Tyrosine kinase inhibitors | |
acamprosate | B2 | Detoxifying Agents, Antidotes |